SDMA Banner web teal-10

Detect decreased GFR with SDMA before the majority of kidney function is lost

Historically, estimation of kidney function has depended on various methods such as glomerular filtration rate (GFR), BUN and creatinine. Standard serum biomarkers are relatively insensitive and increase only when ~75%1 of kidney function is compromised. SDMA can detect loss of kidney function earlier than creatinine and BUN biomarkers.

SDMA shows more sensitivity and reliability

Symmetric dimethylarginine (SDMA) is  produced by all nucleated cells and is cleared almost exclusively by renal excretion. Standard serum biomarkers such as creatinine and BUN are affected by extrarenal factors including body mass and diet, making these biomarkers less sensitive and less reliable.

LC-MS technology leads the way

IDEXX SDMA®, a high throughput assay, has been validated in dogs, cats, horses and rats through a comparison to the LC-MS. All species validations utilize LC-MS (other species are currently in process).

 

Sample Submission

Assay Species Platform  Sample Type Sample Volume*
SDMA  Rat  LC-MS  Serum  50µL
SDMA  Mouse  LC-MS  Serum  50µL
 SDMA  NHP  LC-MS  Serum  100µL
 SDMA  Dog  LC-MS  Serum, Plasma  100µL
 SDMA  Cat  Beckman  Serum, Plasma 100µL
 SDMA Dog  Beckman  Serum, Plasma  100µL
SDMA
Rat   Beckman  Serum  100µL
 
* Minimum volume required
 

1 Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of         
   symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney
   disease. J Vet Intern Med. 2016;30(3):794–802